Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma Inc (NASDAQ: LUMO) is a clinical-stage biotechnology company pioneering therapies for rare endocrine disorders, with a focus on pediatric growth hormone deficiencies. This page aggregates official press releases, clinical trial updates, and strategic developments directly from the company and verified sources.
Investors and stakeholders will find timely updates on LUMO’s pipeline progress, including its lead oral growth hormone secretagogue LUM-201, regulatory milestones, and collaborative research initiatives. The curated content spans clinical data disclosures, partnership announcements, and scientific presentations relevant to rare disease therapeutics.
Key categories include Phase 2 trial results, FDA communications, intellectual property updates, and research collaborations. All materials are sourced to ensure compliance with financial reporting standards and medical accuracy.
Bookmark this page for streamlined access to Lumos Pharma’s latest advancements in transforming treatment paradigms for underserved patient populations. Regularly updated to reflect the company’s evolving role in rare disease innovation.
Lumos Pharma, a biopharmaceutical company, announced the presentation of interim data from its OraGrowtH210 and OraGrowtH212 trials at the Pediatric Endocrine Society's annual meeting in May 2023. The oral presentation, led by Dr. Andrew Dauber, focuses on growth response in subjects treated with LUM-201 for idiopathic Pediatric Growth Hormone Deficiency (iPGHD). Additionally, data from the OraGrowtH212 trial will be showcased in a poster presentation by Dr. Fernando Cassorla. LUM-201 represents a potential alternative to painful growth hormone injections, having received Orphan Drug Designation in the US and EU. This progress highlights Lumos Pharma's commitment to developing effective treatments for rare diseases.
Lumos Pharma, Inc. (NASDAQ:LUMO), based in Austin, Texas, announced that it will report its first quarter 2023 financial results after market close on May 3, 2023. The company is advancing its oral therapeutic candidate, LUM-201, for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials. Following the financial results announcement, Lumos will host a conference call and webcast at 4:30 PM ET, inviting investors and the public to participate in the discussion and Q&A session. LUM-201 aims to provide an alternative to traditional growth hormone injections. It has received Orphan Drug Designation in both the U.S. and EU, highlighting its potential impact in treating rare diseases.
AUSTIN, Texas, March 09, 2023 – Lumos Pharma (NASDAQ:LUMO) announced its participation in Oppenheimer’s 33rd Annual Healthcare Conference, taking place virtually from March 13-15, 2023. Lumos Pharma will present on March 14 from 2:00-2:30 PM EDT and will host one-on-one meetings with investors on the same day. The presentation will focus on the company's oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) currently undergoing Phase 2 trials. Lumos Pharma’s lead candidate, LUM-201, has received Orphan Drug Designation in both the US and EU, offering a potential alternative to traditional growth hormone injections.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
